Case report: Abolishing primary resistance to PD-1 blockade by short-term treatment of lenvatinib in a patient with advanced metastatic renal cell carcinoma

Anti-PD-1 immunotherapy has been extensively used in treatment of patients with advanced metastatic renal cell carcinoma (mRCC). Several prospective clinical trials showed that the combined treatment of anti-PD-1 antibody plus lenvatinib, a potent receptor tyrosine kinase inhibitor (TKI), exhibited...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Tingting, Lin, Xiaotong, Ling, Jing, Wang, Rong, Chen, Yue, Cai, Longmei, Sun, Jingyuan, Wu, Dehua, Xie, Guozhu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895929/
https://www.ncbi.nlm.nih.gov/pubmed/36742302
http://dx.doi.org/10.3389/fimmu.2023.1115691

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895929/
https://www.ncbi.nlm.nih.gov/pubmed/36742302
http://dx.doi.org/10.3389/fimmu.2023.1115691

Ejemplares similares